|
JPH082308B2
(ja)
|
1985-01-28 |
1996-01-17 |
インタ−ナショナル・ジェネティック・エンジニアリング,インコ−ポレイテッド |
araBプロモーターを含有する複製可能な発現ビヒクル
|
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
|
IN165717B
(enExample)
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5202238A
(en)
|
1987-10-27 |
1993-04-13 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
|
US6004781A
(en)
|
1988-01-22 |
1999-12-21 |
The General Hospital Corporation |
Nucleic acid encoding Ig-CD4 fusion proteins
|
|
US5906936A
(en)
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
|
IL86278A
(en)
|
1988-05-04 |
2003-06-24 |
Yeda Res & Dev |
Endowing cells with antibody specificity using chimeric t cell receptor
|
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
US5216132A
(en)
|
1990-01-12 |
1993-06-01 |
Protein Design Labs, Inc. |
Soluble t-cell antigen receptor chimeric antigens
|
|
US20020004052A1
(en)
|
1990-05-08 |
2002-01-10 |
David Berd |
Composition comprising a tumor cell extract and method of using the composition
|
|
US5914109A
(en)
|
1990-06-15 |
1999-06-22 |
New York University |
Heterohybridomas producing human monoclonal antibodies to HIV-1
|
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
US20020111474A1
(en)
|
1990-12-14 |
2002-08-15 |
Capon Daniel J. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
US6407221B1
(en)
|
1990-12-14 |
2002-06-18 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
ATE145428T1
(de)
|
1990-12-14 |
1996-12-15 |
Cell Genesys Inc |
Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
|
|
US5912170A
(en)
|
1991-03-07 |
1999-06-15 |
The General Hospital Corporation |
Redirection of cellular immunity by protein-tyrosine kinase chimeras
|
|
US5851828A
(en)
|
1991-03-07 |
1998-12-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
|
IL101147A
(en)
|
1991-03-07 |
2004-06-20 |
Gen Hospital Corp |
Redirection of cellular immunity by receptor chimeras
|
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
US6753162B1
(en)
|
1991-03-07 |
2004-06-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
|
US5843728A
(en)
|
1991-03-07 |
1998-12-01 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
JPH06505396A
(ja)
|
1991-03-08 |
1994-06-23 |
サイトメッド,インコーポレイテッド |
可溶性cd28タンパク質およびそれを用いる治療方法
|
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
|
JPH07500343A
(ja)
|
1991-10-21 |
1995-01-12 |
セル ジェネシス,インコーポレイティド |
結合細胞及び免疫抑制の療法
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
|
US5372930A
(en)
|
1992-09-16 |
1994-12-13 |
The United States Of America As Represented By The Secretary Of The Navy |
Sensor for ultra-low concentration molecular recognition
|
|
US7105159B1
(en)
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
|
US6953668B1
(en)
|
1992-11-05 |
2005-10-11 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
EP1757695A3
(en)
|
1992-11-05 |
2008-02-27 |
Sloan Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US5861156A
(en)
|
1993-01-08 |
1999-01-19 |
Creative Biomolecules |
Methods of delivering agents to target cells
|
|
WO1994022914A1
(en)
|
1993-04-06 |
1994-10-13 |
Fred Hutchinson Cancer Research Center |
Chimeric cytokine receptors in lymphocytes
|
|
US5834256A
(en)
|
1993-06-11 |
1998-11-10 |
Cell Genesys, Inc. |
Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
|
|
US6051427A
(en)
|
1993-06-11 |
2000-04-18 |
Cell Genesys, Inc. |
Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
|
|
US5525503A
(en)
|
1993-09-28 |
1996-06-11 |
Dana-Farber Cancer Institute, Inc. |
Signal transduction via CD28
|
|
WO1996026272A1
(en)
|
1995-02-24 |
1996-08-29 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
US5935818A
(en)
|
1995-02-24 |
1999-08-10 |
Sloan-Kettering Institute For Cancer Research |
Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
|
|
KR100373813B1
(ko)
|
1994-05-02 |
2003-10-08 |
베른트 그로너 |
이관능성단백질,그의제조및용도
|
|
US5798100A
(en)
|
1994-07-06 |
1998-08-25 |
Immunomedics, Inc. |
Multi-stage cascade boosting vaccine
|
|
US7354587B1
(en)
|
1994-07-06 |
2008-04-08 |
Immunomedics, Inc. |
Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
|
|
US6083751A
(en)
|
1994-11-01 |
2000-07-04 |
Targeted Genetics Corporation |
Chimeric receptors for the generation of selectively-activatable TH-independent cytotoxic T cells
|
|
US5837544A
(en)
|
1995-02-02 |
1998-11-17 |
Cell Genesys, Inc. |
Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
|
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
|
US5830755A
(en)
|
1995-03-27 |
1998-11-03 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
T-cell receptors and their use in therapeutic and diagnostic methods
|
|
WO1997004752A1
(en)
|
1995-07-26 |
1997-02-13 |
Duramed Pharmaceuticals, Inc. |
Pharmaceutical compositions of conjugated estrogens and methods for their use
|
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
|
WO1997034634A1
(en)
|
1996-03-20 |
1997-09-25 |
Sloan-Kettering Institute For Cancer Research |
Single chain fv constructs of anti-ganglioside gd2 antibodies
|
|
US6261787B1
(en)
|
1996-06-03 |
2001-07-17 |
Case Western Reserve University |
Bifunctional molecules for delivery of therapeutics
|
|
US5969102A
(en)
|
1997-03-03 |
1999-10-19 |
St. Jude Children's Research Hospital |
Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
|
|
US20020018783A1
(en)
|
1997-03-20 |
2002-02-14 |
Michel Sadelain |
Fusion proteins of a single chain antibody and cd28 and uses thereof
|
|
AU8142598A
(en)
|
1997-06-11 |
1998-12-30 |
New York University |
Prenylcysteine carboxyl methyltransferase, dna encoding same, and a method of screening for inhibitors thereof
|
|
US6759243B2
(en)
|
1998-01-20 |
2004-07-06 |
Board Of Trustees Of The University Of Illinois |
High affinity TCR proteins and methods
|
|
US20090011984A1
(en)
|
1998-02-23 |
2009-01-08 |
Seppo Yla-Herttuala |
Biotin-binding receptor molecules
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
WO2000014257A1
(en)
|
1998-09-04 |
2000-03-16 |
Sloan-Kettering Institute For Cancer Research |
Fusion receptors specific for prostate-specific membrane antigen and uses thereof
|
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
WO2000023087A1
(en)
|
1998-10-21 |
2000-04-27 |
Sunol Molecular Corporation |
Polyspecific binding molecules and uses thereof
|
|
US7217421B1
(en)
|
1998-11-03 |
2007-05-15 |
Cell Genesys, Inc. |
Cancer-associated antigens and methods of their identification and use
|
|
IL145067A0
(en)
|
1999-03-01 |
2002-06-30 |
Cell Genesys Inc |
Nucleic acid composition containing a first sequence encoding a chimeric cyclin-dependent kinase protein and a second sequence encoding an adenovirus e4 protein
|
|
AU4418900A
(en)
|
1999-04-16 |
2000-11-02 |
Celltech Therapeutics Limited |
Synthetic transmembrane components
|
|
US6699972B1
(en)
|
1999-06-25 |
2004-03-02 |
Academia Sinica |
Chimeric protein and method of controlling tumor growth using the protein
|
|
ATE360031T1
(de)
|
2000-01-03 |
2007-05-15 |
Tr Associates L L C |
Chimäre proteine und anwendungen
|
|
DE60128070T2
(de)
|
2000-02-14 |
2008-01-10 |
The Regents Of The University Of California, Oakland |
Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors
|
|
US6770749B2
(en)
|
2000-02-22 |
2004-08-03 |
City Of Hope |
P53-specific T cell receptor for adoptive immunotherapy
|
|
NZ521898A
(en)
|
2000-03-31 |
2004-11-26 |
Purdue Research Foundation |
Use of a ligand-immunogen conjugate such as folate-FITC for enhancing an endogenous immune response
|
|
AU2001255580A1
(en)
|
2000-04-21 |
2001-12-11 |
Rutgers, The State University Of New Jersey |
Methods and compositions for the diagnosis of schizophrenia
|
|
US6524572B1
(en)
|
2000-06-26 |
2003-02-25 |
Rainbow Therapeutic Company |
Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy
|
|
ATE389668T1
(de)
|
2000-07-31 |
2008-04-15 |
Greenpeptide Co Ltd |
Tumorantigen
|
|
US7666424B2
(en)
|
2001-10-17 |
2010-02-23 |
Sloan-Kettering Institute For Cancer Research |
Methods of preparing and using single chain anti-tumor antibodies
|
|
AU2001297703B2
(en)
|
2000-11-07 |
2006-10-19 |
City Of Hope |
CD19-specific redirected immune cells
|
|
US20020132983A1
(en)
|
2000-11-30 |
2002-09-19 |
Junghans Richard P. |
Antibodies as chimeric effector cell receptors against tumor antigens
|
|
US7723111B2
(en)
|
2001-03-09 |
2010-05-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Activated dual specificity lymphocytes and their methods of use
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
CA2445746C
(en)
|
2001-04-30 |
2012-09-18 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
US7514537B2
(en)
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
|
US7939059B2
(en)
|
2001-12-10 |
2011-05-10 |
California Institute Of Technology |
Method for the generation of antigen-specific lymphocytes
|
|
US20070031438A1
(en)
|
2001-12-10 |
2007-02-08 |
Junghans Richard P |
Antibodies as chimeric effector cell receptors against tumor antigens
|
|
US20030170238A1
(en)
|
2002-03-07 |
2003-09-11 |
Gruenberg Micheal L. |
Re-activated T-cells for adoptive immunotherapy
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
EP2181595A1
(en)
|
2002-08-16 |
2010-05-05 |
Yeda Research And Development Company Ltd. |
Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
|
|
US8809504B2
(en)
|
2002-09-03 |
2014-08-19 |
Vit Lauermann |
Inhibitor which is deactivatable by a reagent produced by a target cell
|
|
DE10244457A1
(de)
|
2002-09-24 |
2004-04-01 |
Johannes-Gutenberg-Universität Mainz |
Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
|
|
US20060018878A1
(en)
|
2003-03-11 |
2006-01-26 |
City Of Hope |
Dual antigen specific T cells with trafficking ability
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
US20050113564A1
(en)
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US20130266551A1
(en)
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US7196062B2
(en)
|
2004-02-18 |
2007-03-27 |
Wisconsin Alumni Research Foundation |
Method for treating glaucoma
|
|
DE602005015687D1
(de)
|
2004-03-02 |
2009-09-10 |
Cellectar Inc |
Phospholipid-analoga für die behandlung von krebs
|
|
PL2921500T3
(pl)
|
2004-07-10 |
2024-02-05 |
The Institute For Cancer Research |
Genetycznie zmodyfikowane ludzkie linie komórkowe naturalni zabójcy
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
US7994298B2
(en)
|
2004-09-24 |
2011-08-09 |
Trustees Of Dartmouth College |
Chimeric NK receptor and methods for treating cancer
|
|
CA2590401C
(en)
|
2004-10-08 |
2015-04-21 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Adoptive immunotherapy with enhanced t lymphocyte survival
|
|
WO2007024249A2
(en)
|
2004-11-10 |
2007-03-01 |
Macrogenics, Inc. |
Engineering fc antibody regions to confer effector function
|
|
WO2007044033A2
(en)
|
2004-12-07 |
2007-04-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
|
|
US20070036773A1
(en)
|
2005-08-09 |
2007-02-15 |
City Of Hope |
Generation and application of universal T cells for B-ALL
|
|
US8466263B2
(en)
|
2005-12-02 |
2013-06-18 |
Dana-Farber Cancer Institute, Inc. |
Carbonic anhydrase IX (G250) anitbodies
|
|
US7919079B2
(en)
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
|
EP1900752A1
(en)
|
2006-09-15 |
2008-03-19 |
DOMPE' pha.r.ma s.p.a. |
Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
|
|
WO2008045437A2
(en)
|
2006-10-09 |
2008-04-17 |
The General Hospital Corporation |
Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
|
|
US9334330B2
(en)
|
2006-10-10 |
2016-05-10 |
Universite De Nantes |
Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers
|
|
US8685752B2
(en)
|
2006-11-03 |
2014-04-01 |
Purdue Research Foundation |
Ex vivo flow cytometry method and device
|
|
WO2008060510A2
(en)
|
2006-11-13 |
2008-05-22 |
Sangamo Biosciences, Inc. |
Zinc finger nuclease for targeting the human glucocorticoid receptor locus
|
|
US20080131415A1
(en)
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
|
US8748405B2
(en)
|
2007-01-26 |
2014-06-10 |
City Of Hope |
Methods and compositions for the treatment of cancer or other diseases
|
|
ATE504647T1
(de)
|
2007-01-30 |
2011-04-15 |
Forerunner Pharma Res Co Ltd |
Chimärer fc gamma rezeptor und verfahren zur bestimmung von adcc-aktivität unter verwendung des rezeptors
|
|
HUE030386T2
(en)
|
2007-01-31 |
2017-05-29 |
Yeda Res & Dev |
Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
|
|
US8859229B2
(en)
|
2007-02-02 |
2014-10-14 |
Yale University |
Transient transfection with RNA
|
|
US8865169B2
(en)
|
2007-02-20 |
2014-10-21 |
Tufts University |
Methods and systems for multi-antibody therapies
|
|
PL2856876T3
(pl)
|
2007-03-30 |
2018-06-29 |
Memorial Sloan-Kettering Cancer Center |
Konstytutywna ekspresja ligandów kostymulujących na limfocytach T poddanych transferowi adoptywnemu
|
|
WO2009020093A1
(ja)
|
2007-08-09 |
2009-02-12 |
Daiichi Sankyo Company, Limited |
デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム
|
|
WO2009091826A2
(en)
|
2008-01-14 |
2009-07-23 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
|
|
WO2009117117A1
(en)
|
2008-03-19 |
2009-09-24 |
Altor Bioscience Corporation |
T cell receptor fusions and conjugates and methods of use there of
|
|
JP5779090B2
(ja)
|
2008-04-09 |
2015-09-16 |
マックスサイト インコーポレーティッド |
新規に単離された細胞の治療組成物の操作および送達
|
|
PT2132228E
(pt)
|
2008-04-11 |
2011-10-11 |
Emergent Product Dev Seattle |
Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
|
|
US20090324630A1
(en)
|
2008-04-21 |
2009-12-31 |
Jensen Michael C |
Fusion multiviral chimeric antigen
|
|
US8822647B2
(en)
|
2008-08-26 |
2014-09-02 |
City Of Hope |
Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
|
|
US8546425B2
(en)
|
2008-09-17 |
2013-10-01 |
Purdue Research Foundation |
Folate receptor binding conjugates of antifolates
|
|
EP2364368B1
(en)
|
2008-11-07 |
2014-01-15 |
Sequenta, Inc. |
Methods of monitoring conditions by sequence analysis
|
|
EP3936122A1
(en)
|
2008-11-24 |
2022-01-12 |
Massachusetts Institute Of Technology |
Methods and compositions for localized agent delivery
|
|
US8877199B2
(en)
|
2009-05-15 |
2014-11-04 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
B cell surface reactive antibodies
|
|
US20100322909A1
(en)
|
2009-06-17 |
2010-12-23 |
The University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Th1-associated micrornas and their use for tumor immunotherapy
|
|
US8465743B2
(en)
|
2009-10-01 |
2013-06-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
|
|
CN102597222B
(zh)
|
2009-10-27 |
2015-07-15 |
因缪尼卡姆股份公司 |
用于增殖抗原特异性t细胞的方法
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
US9273283B2
(en)
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
|
ES2717629T3
(es)
|
2009-11-03 |
2019-06-24 |
Hope City |
Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
|
|
JP2013512694A
(ja)
|
2009-12-08 |
2013-04-18 |
ウィルソン ウォルフ マニュファクチャリング コーポレイション |
養子細胞療法のための細胞を培養する方法
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
ES2680915T3
(es)
|
2010-01-28 |
2018-09-11 |
The Children's Hospital Of Philadelphia |
Plataforma de fabricación escalable para la purificación de vectores virales y vectores virales purificados de este modo para su utilización en terapia génica
|
|
EP2531216B1
(en)
|
2010-02-04 |
2019-03-27 |
The Trustees Of The University Of Pennsylvania |
Icos critically regulates the expansion and function of inflammatory human th17 cells
|
|
CA2789446A1
(en)
|
2010-02-12 |
2011-08-18 |
Oncomed Pharmaceuticals, Inc. |
Methods for identifying and isolating cells expressing a polypeptide
|
|
SA111320200B1
(ar)
|
2010-02-17 |
2014-02-16 |
ديبيوفارم اس ايه |
مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
|
|
US9833480B2
(en)
|
2010-04-14 |
2017-12-05 |
Prospect Chartercare, Llc |
Methods and compositions for treating HIV
|
|
WO2011140170A1
(en)
|
2010-05-04 |
2011-11-10 |
Yeda Research And Development Co. Ltd. |
Immunotherapy using redirected allogeneic cells
|
|
US9089520B2
(en)
|
2010-05-21 |
2015-07-28 |
Baylor College Of Medicine |
Methods for inducing selective apoptosis
|
|
WO2011159847A2
(en)
|
2010-06-15 |
2011-12-22 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
|
|
US9163258B2
(en)
|
2010-07-23 |
2015-10-20 |
Fred Hutchinson Cancer Research Center |
Method for the treatment of obesity
|
|
DE102010036122A1
(de)
|
2010-09-01 |
2012-03-01 |
Nora Systems Gmbh |
Bodenbelag
|
|
EP2614077B1
(en)
|
2010-09-08 |
2016-08-17 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Chimeric antigen receptors with an optimized hinge region
|
|
WO2012136231A1
(en)
|
2010-09-08 |
2012-10-11 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Interleukin 15 as selectable marker for gene transfer in lymphocytes
|
|
WO2012033885A1
(en)
|
2010-09-08 |
2012-03-15 |
Baylor College Of Medicine |
Immunotherapy of cancer using genetically engineered gd2-specific t cells
|
|
CN103124740B
(zh)
|
2010-09-21 |
2015-09-02 |
美国卫生和人力服务部 |
抗-ssx-2t细胞受体和相关材料及使用方法
|
|
CA2811297C
(en)
|
2010-09-26 |
2016-10-25 |
Donald O'keefe |
Method of recombinant macromolecular production
|
|
US9845362B2
(en)
|
2010-10-08 |
2017-12-19 |
The University Of North Carolina At Charlotte |
Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
|
|
WO2012054825A1
(en)
|
2010-10-22 |
2012-04-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mage-a3 t cell receptors and related materials and methods of use
|
|
WO2012076059A1
(en)
|
2010-12-09 |
2012-06-14 |
Stichting Het Nederlands Kanker Instituut |
Immune restricted peptides with increased efficacy
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP3693017A1
(en)
|
2010-12-14 |
2020-08-12 |
University of Maryland, Baltimore |
Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
|
|
US9402865B2
(en)
|
2011-01-18 |
2016-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating cancer
|
|
KR101944557B1
(ko)
|
2011-02-11 |
2019-01-30 |
메모리얼 슬로안 케터링 캔서 센터 |
에이치엘에이 제한된, 펩타이드특이성 항원 결합 단백질
|
|
US9987308B2
(en)
|
2011-03-23 |
2018-06-05 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
EP2502934B1
(en)
|
2011-03-24 |
2018-01-17 |
Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds
|
|
AU2012236068A1
(en)
|
2011-04-01 |
2013-10-17 |
Eureka Therapeutics, Inc. |
T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
|
|
TR201815488T4
(tr)
|
2011-04-08 |
2018-11-21 |
Health |
Anti-epidermal büyüme faktör reseptörü varyant III kimerik antijen reseptörleri ve kanser tedavisi için kullanımı.
|
|
WO2012140127A2
(en)
|
2011-04-13 |
2012-10-18 |
Immunicum Ab |
Method for priming of t cells
|
|
EP2697367B1
(en)
|
2011-04-13 |
2018-12-19 |
Immunicum AB |
Method for proliferation of antigen-specific t cells
|
|
WO2012145469A1
(en)
|
2011-04-19 |
2012-10-26 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies specific for glypican-3 and use thereof
|
|
GB201108236D0
(en)
|
2011-05-17 |
2011-06-29 |
Ucl Business Plc |
Method
|
|
PH12014500247A1
(en)
|
2011-07-29 |
2014-03-24 |
Univ Pennsylvania |
Switch costimulatory receptors
|
|
EP2747781B1
(en)
|
2011-08-23 |
2017-11-15 |
Roche Glycart AG |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
US9833476B2
(en)
|
2011-08-31 |
2017-12-05 |
The Trustees Of Dartmouth College |
NKP30 receptor targeted therapeutics
|
|
CA3114877C
(en)
|
2011-09-15 |
2023-09-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
|
|
US10421960B2
(en)
|
2011-09-16 |
2019-09-24 |
The Trustees Of The University Of Pennsylvania |
RNA engineered T cells for the treatment of cancer
|
|
EP2755487B1
(en)
|
2011-09-16 |
2018-12-19 |
Baylor College Of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
|
US9708384B2
(en)
|
2011-09-22 |
2017-07-18 |
The Trustees Of The University Of Pennsylvania |
Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
|
|
WO2013051718A1
(ja)
|
2011-10-07 |
2013-04-11 |
国立大学法人三重大学 |
キメラ抗原受容体
|
|
IN2014CN02906A
(enExample)
|
2011-10-20 |
2015-07-03 |
Us Health |
|
|
US9688740B2
(en)
|
2011-10-26 |
2017-06-27 |
National Cancer Center |
Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy
|
|
WO2013063019A1
(en)
|
2011-10-28 |
2013-05-02 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells
|
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
|
US9422351B2
(en)
|
2011-11-03 |
2016-08-23 |
The Trustees Of The University Of Pennsylvania |
Isolated B7-H4 specific compositions and methods of use thereof
|
|
US20140322216A1
(en)
|
2011-11-08 |
2014-10-30 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
|
US10208086B2
(en)
|
2011-11-11 |
2019-02-19 |
Fred Hutchinson Cancer Research Center |
Cyclin A1-targeted T-cell immunotherapy for cancer
|
|
EP2790708B1
(en)
|
2011-12-16 |
2024-10-23 |
Targetgene Biotechnologies Ltd. |
Compositions and methods for modifying a predetermined target nucleic acid sequence
|
|
EP3539982B1
(en)
|
2011-12-23 |
2025-02-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
US20140370012A1
(en)
|
2012-01-27 |
2014-12-18 |
Gliknik Inc. |
Fusion proteins comprising igg2 hinge domains
|
|
EP3594245A1
(en)
|
2012-02-13 |
2020-01-15 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
SG11201404769UA
(en)
|
2012-02-22 |
2014-11-27 |
Univ Pennsylvania |
Use of icos-based cars to enhance antitumor activity and car persistence
|
|
SG11201404284SA
(en)
|
2012-02-22 |
2014-10-30 |
Univ Pennsylvania |
Use of the cd2 signaling domain in second-generation chimeric antigen receptors
|
|
WO2013126726A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Double transgenic t cells comprising a car and a tcr and their methods of use
|
|
CA2868121C
(en)
|
2012-03-23 |
2021-06-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
ES3065694T3
(en)
|
2012-04-11 |
2026-05-07 |
Us Health |
Chimeric antigen receptors targeting b-cell maturation antigen
|
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
|
CN107557334B
(zh)
|
2012-05-03 |
2021-06-25 |
弗雷德哈钦森癌症研究中心 |
增强亲和力的t细胞受体及其制备方法
|
|
ES2719495T5
(en)
|
2012-05-07 |
2025-09-10 |
Dartmouth College |
Anti-b7-h6 antibody, fusion proteins, and methods of using the same
|
|
CN104507963B
(zh)
|
2012-05-22 |
2017-12-15 |
美国卫生和人力服务部 |
鼠抗‑ny‑eso‑1 t细胞受体
|
|
BR112014029161A2
(pt)
|
2012-05-22 |
2017-06-27 |
Genentech Inc |
benzamidas n-substituídas e seu uso no tratamento de dor
|
|
EP4541818A3
(en)
|
2012-05-25 |
2025-07-23 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
US9409994B2
(en)
|
2012-06-01 |
2016-08-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High-affinity monoclonal antibodies to glypican-3 and use thereof
|
|
CN104662153A
(zh)
|
2012-06-08 |
2015-05-27 |
学校法人近畿大学 |
针对转运体的抗体及其用途
|
|
JP5863585B2
(ja)
|
2012-07-11 |
2016-02-16 |
三菱電機株式会社 |
大信号等価回路モデルを用いたトランジスタ特性計算装置
|
|
AU2013289971A1
(en)
|
2012-07-13 |
2015-01-22 |
The Trustees Of The University Of Pennsylvania |
Enhancing activity of CAR T cells by co-introducing a bispecific antibody
|
|
LT3338794T
(lt)
|
2012-07-13 |
2020-05-25 |
The Trustees Of The University Of Pennsylvania |
Car priešnavikinio aktyvumo toksiškumo reguliavimas
|
|
CN112375846A
(zh)
|
2012-07-13 |
2021-02-19 |
宾夕法尼亚大学董事会 |
评估用于施用的转导t细胞的适用性的方法
|
|
WO2014011987A1
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for regulating car t cells
|
|
CN102775500A
(zh)
|
2012-08-03 |
2012-11-14 |
郑骏年 |
嵌合抗原受体iRGD-scFv(G250)-CD8-CD28-CD137-CD3ζ及其用途
|
|
PL3824905T3
(pl)
|
2012-08-20 |
2025-05-05 |
Fred Hutchinson Cancer Center |
Sposób i kompozycje do immunoterapii komórkowej
|
|
WO2014031476A1
(en)
|
2012-08-21 |
2014-02-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
|
ES2714523T3
(es)
|
2012-09-04 |
2019-05-28 |
Cellectis |
Receptor quimérico de antígenos multicatenario y usos del mismo
|
|
DK2895509T3
(da)
|
2012-09-14 |
2020-03-09 |
Us Health |
T-cellereceptorer, som genkender mhc-klasse ii begrænset mage-a3
|
|
WO2014052064A1
(en)
|
2012-09-27 |
2014-04-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
|
AR092745A1
(es)
|
2012-10-01 |
2015-04-29 |
Univ Pennsylvania |
Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
|
|
SG11201502598SA
(en)
|
2012-10-02 |
2015-05-28 |
Sloan Kettering Inst Cancer |
Compositions and methods for immunotherapy
|
|
WO2014055771A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
EP3763810A3
(en)
|
2012-10-10 |
2021-07-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
WO2014059248A1
(en)
|
2012-10-12 |
2014-04-17 |
Philadelphia Health & Education Corporation D/B/A/ Drexel |
Mir-155 enhancement of cd8+ t cell immunity
|
|
UY35103A
(es)
|
2012-10-29 |
2014-05-30 |
Glaxo Group Ltd |
Compuestos de cefem 2-sustituidos
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
EP4282419A1
(en)
*
|
2012-12-20 |
2023-11-29 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
WO2014099671A1
(en)
|
2012-12-20 |
2014-06-26 |
Bluebird Bio, Inc. |
Chimeric antigen receptors and immune cells targeting b cell malignancies
|
|
WO2014117121A1
(en)
|
2013-01-28 |
2014-07-31 |
St. Jude Children's Research Hospital, Inc. |
A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
|
|
AU2014214850C1
(en)
|
2013-02-06 |
2018-12-06 |
Celgene Corporation |
Modified T lymphocytes having improved specificity
|
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
SI3300745T1
(sl)
|
2013-02-15 |
2020-01-31 |
The Regents Of The University Of California |
Himerni antigenski receptor in postopki njihove uporabe
|
|
US9573988B2
(en)
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
|
LT2958943T
(lt)
|
2013-02-20 |
2020-01-27 |
The Trustees Of The University Of Pennsylvania |
Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
|
|
US9434935B2
(en)
|
2013-03-10 |
2016-09-06 |
Bellicum Pharmaceuticals, Inc. |
Modified caspase polypeptides and uses thereof
|
|
US9587237B2
(en)
|
2013-03-14 |
2017-03-07 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
EP2968502B1
(en)
|
2013-03-14 |
2020-08-26 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlling t cell proliferation
|
|
US9499855B2
(en)
|
2013-03-14 |
2016-11-22 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
JP6501270B2
(ja)
|
2013-03-14 |
2019-04-17 |
ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ |
標的化剤抗体抱合体およびその使用
|
|
US9402888B2
(en)
|
2013-03-14 |
2016-08-02 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for treating cancer
|
|
US9561291B2
(en)
|
2013-03-15 |
2017-02-07 |
Imre Kovesdi |
Methods of targeting T-cells to tumors
|
|
CA2907397C
(en)
|
2013-03-15 |
2022-11-22 |
Anthrogenesis Corporation |
Modified t lymphocytes
|
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
US9446105B2
(en)
|
2013-03-15 |
2016-09-20 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor specific for folate receptor β
|
|
US9393268B2
(en)
|
2013-03-15 |
2016-07-19 |
Thomas Jefferson University |
Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
|
US9790282B2
(en)
|
2013-03-25 |
2017-10-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
|
|
EP3974520A1
(en)
|
2013-05-14 |
2022-03-30 |
Board of Regents, The University of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
EP3730615A3
(en)
|
2013-05-15 |
2020-12-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
WO2014190273A1
(en)
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
DK3309248T3
(da)
|
2013-05-29 |
2021-08-02 |
Cellectis |
Fremgangsmåde til manipulering af T-celler til immunterapi under anvendelse af et RNA-guidet CAS-nuklease-system
|
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
|
CA2912172A1
(en)
|
2013-06-05 |
2014-12-11 |
Bellicum Pharmaceuticals, Inc. |
Methods for inducing partial apoptosis using caspase polypeptides
|
|
US9738726B2
(en)
|
2013-06-11 |
2017-08-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HER2-specific monoclonal antibodies and conjugates thereof
|
|
SG10201902380SA
(en)
|
2013-06-25 |
2019-04-29 |
Vaccinex Inc |
Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
|
|
WO2015031771A2
(en)
|
2013-08-30 |
2015-03-05 |
Board Of Regents, The University Of Texas System |
Administration of kynurenine depleting enzymes for tumor therapy
|
|
US20150073154A1
(en)
|
2013-09-11 |
2015-03-12 |
Equip, Llc |
Discrete PEG Based Dyes
|
|
ES2764833T3
(es)
|
2013-10-11 |
2020-06-04 |
The United States Of America Represented By The Sec Dep Of Health And Human Services |
Anticuerpos contra TEM8 y su uso
|
|
CN105829349B
(zh)
|
2013-10-15 |
2023-02-03 |
斯克利普斯研究所 |
肽嵌合抗原受体t细胞开关和其用途
|
|
AU2014337385B2
(en)
*
|
2013-10-15 |
2020-04-30 |
The Scripps Research Institute |
Chimeric antigen receptor T cell switches and uses thereof
|
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
|
AU2014342020C1
(en)
|
2013-10-31 |
2019-09-05 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof
|
|
US20160333108A1
(en)
|
2014-01-13 |
2016-11-17 |
Stephen J. Forman |
CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
|
|
EP3094354B1
(en)
|
2014-01-14 |
2018-10-17 |
Cellectis |
Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish
|
|
US9694033B2
(en)
|
2014-01-24 |
2017-07-04 |
The Cleveland Clinic Foundation |
IL-9 secreting CD8+ Tc9 cells and methods of treating cancer
|
|
WO2015123496A1
(en)
|
2014-02-14 |
2015-08-20 |
Immune Design Corp. |
Immunotherapy of cancer through combination of local and systemic immune stimulation
|
|
US10934346B2
(en)
|
2014-02-14 |
2021-03-02 |
Bellicum Pharmaceuticals, Inc. |
Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
|
|
JP6447933B2
(ja)
|
2014-02-21 |
2019-01-09 |
アイビーシー ファーマスーティカルズ,インコーポレイテッド |
Trop−2発現細胞に対する免疫応答を誘発することによる疾患治療
|
|
CN106471004A
(zh)
|
2014-02-28 |
2017-03-01 |
麦吉尔大学学术发展皇家学院 |
作为用于免疫疗法的apc活化剂的tc‑ptp抑制剂
|
|
KR101605421B1
(ko)
|
2014-03-05 |
2016-03-23 |
국립암센터 |
B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
|
|
GB201403875D0
(en)
|
2014-03-05 |
2014-04-16 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
US20150328292A1
(en)
|
2014-03-07 |
2015-11-19 |
Bellicum Pharmaceuticals, Inc. |
Caspase polypeptides having modified activity and uses thereof
|
|
US20170081411A1
(en)
|
2014-03-15 |
2017-03-23 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
IL322264A
(en)
|
2014-04-07 |
2025-09-01 |
Novartis Ag |
Cancer treatment using chimeric antigen receptor (CAR) against CD19
|
|
WO2015157299A2
(en)
|
2014-04-09 |
2015-10-15 |
Seattle Children's Hospital (Dba Seattle Children's Research Institute |
Inhibition of lactate dehydrogenase 5 (ldh-5) binding, incorporation, internalization and/or endocytosis to immune cells
|
|
AU2015243849B2
(en)
|
2014-04-10 |
2020-12-17 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Transgene genetic tags and methods of use
|
|
US20170158749A1
(en)
|
2014-04-23 |
2017-06-08 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) and methods for making and using the same
|
|
GB2540694A
(en)
|
2014-04-29 |
2017-01-25 |
Seattle Children's Hospital (Dba Seattle Children's Res Institute) |
CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
|
|
US20170210818A1
(en)
|
2014-06-06 |
2017-07-27 |
The California Institute For Biomedical Research |
Constant region antibody fusion proteins and compositions thereof
|
|
US9885021B2
(en)
|
2014-06-12 |
2018-02-06 |
Children's National Medical Center |
Generation of broadly-specific, virus-immune cells targeting multiple HIV antigens for preventive and therapeutic use
|
|
US9777061B2
(en)
|
2014-07-21 |
2017-10-03 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
|
MY181834A
(en)
|
2014-07-21 |
2021-01-08 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
JP6736540B2
(ja)
|
2014-07-21 |
2020-08-05 |
ノバルティス アーゲー |
Cll−1キメラ抗原受容体を使用した癌の処置
|
|
PL3177640T3
(pl)
|
2014-08-08 |
2020-11-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania
|
|
US11141494B2
(en)
|
2014-08-09 |
2021-10-12 |
Purdue Research Foundation |
Development of neurokinin-1 receptor-binding agent delivery conjugates
|
|
KR20220150428A
(ko)
|
2014-08-12 |
2022-11-10 |
안트로제네시스 코포레이션 |
림프절 b 세포 구역, 피부, 또는 위장관으로 귀소하도록 조작된 car-t 림프구
|
|
SG11201700770PA
(en)
|
2014-08-19 |
2017-03-30 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
CA2959168A1
(en)
|
2014-09-02 |
2016-03-10 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
|
|
EP3587446A1
(en)
|
2014-09-19 |
2020-01-01 |
City of Hope |
Costimulatory chimeric antigen receptor t cells targeting il13 r alpha 2
|
|
WO2016054520A2
(en)
|
2014-10-03 |
2016-04-07 |
The California Institute For Biomedical Research |
Engineered cell surface proteins and uses thereof
|
|
WO2016057850A1
(en)
|
2014-10-09 |
2016-04-14 |
Seattle Children' S Hospital (Dba Seattle Children' S Research Institute) |
Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid
|
|
JP6613312B2
(ja)
|
2014-10-14 |
2019-11-27 |
ジ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンティッド バイ ザ セクレタリー,デパートメント オブ ヘルス アンド ヒューマン サービシズ |
膵臓癌を処置するためのペプチドをベースとする方法
|
|
RU2739794C2
(ru)
|
2014-10-31 |
2020-12-28 |
Массачусетс Инститьют Оф Текнолоджи |
Доставка биомолекул в клетки иммунной системы
|
|
KR20170075785A
(ko)
|
2014-11-05 |
2017-07-03 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
유전자 변형된 면역 효과기 세포 및 면역 효과기 세포의 증식용 가공된 세포
|
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
JP6846345B2
(ja)
|
2014-11-14 |
2021-03-24 |
マサチューセッツ インスティテュート オブ テクノロジー |
破壊及び場による細胞への化合物及び組成物の送達
|
|
SI3750545T1
(sl)
|
2014-11-17 |
2024-06-28 |
Cellectar Biosciences, Inc. |
Analogi fosfolipidnega etra kot nosilci zdravil, ki ciljajo na raka
|
|
HK1251862A1
(zh)
|
2014-12-02 |
2019-04-26 |
普拉斯派克特查特凯尔Rwmc有限责任公司 |
治疗癌症的方法和组合物
|
|
CA2969704C
(en)
|
2014-12-05 |
2023-05-02 |
City Of Hope |
Cs1 targeted chimeric antigen receptor-modified t cells
|
|
DK3234145T3
(da)
|
2014-12-15 |
2019-08-19 |
Bellicum Pharmaceuticals Inc |
Fremgangsmåde til kontrollered aktivering eller eliminering af terapeutiske celler
|
|
CA3008162A1
(en)
|
2014-12-15 |
2016-06-23 |
The Regents Of The University Of California |
Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
|
|
EP3234144B1
(en)
|
2014-12-15 |
2020-08-26 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlled elimination of therapeutic cells
|
|
US20190054117A1
(en)
|
2014-12-19 |
2019-02-21 |
Novartis Ag |
Dimerization switches and uses thereof
|
|
IL301458A
(en)
|
2014-12-24 |
2023-05-01 |
Autolus Ltd |
A cell that simultaneously expresses a chimeric antigen receptor (CAR) of 19CD and 22CD
|
|
CN107567461A
(zh)
|
2014-12-29 |
2018-01-09 |
诺华股份有限公司 |
制备嵌合抗原受体表达细胞的方法
|
|
EP3240551A4
(en)
|
2014-12-31 |
2018-08-08 |
Anthrogenesis Corporation |
Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
|
|
US9765330B1
(en)
|
2015-01-09 |
2017-09-19 |
Nant Holdings Ip, Llc |
Compositions and methods for reduction of allograft recognition and rejection
|
|
CN107530376A
(zh)
|
2015-02-18 |
2018-01-02 |
恩立夫克治疗有限责任公司 |
用于癌症治疗的联合免疫疗法和细胞因子控制疗法
|
|
WO2016138034A1
(en)
|
2015-02-24 |
2016-09-01 |
The Regents Of The University Of California |
Binding-triggered transcriptional switches and methods of use thereof
|
|
KR102133857B1
(ko)
|
2015-03-02 |
2020-07-20 |
이노베이티브 셀룰러 테라퓨틱스 코퍼레이션 리미티드 |
Pd-l1에 의해 유도된 면역관용의 감소
|
|
US9777064B2
(en)
|
2015-03-17 |
2017-10-03 |
Chimera Bioengineering, Inc. |
Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof
|
|
EP3271463A4
(en)
|
2015-03-18 |
2018-08-01 |
Baylor College of Medicine |
Her2/erbb2 chimeric antigen receptor
|
|
US9717745B2
(en)
|
2015-03-19 |
2017-08-01 |
Zhejiang DTRM Biopharma Co. Ltd. |
Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
|
|
WO2016154621A1
(en)
|
2015-03-26 |
2016-09-29 |
The California Institute For Biomedical Research |
SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
|
|
WO2016154628A1
(en)
|
2015-03-26 |
2016-09-29 |
Xiuli Wang |
Bi-specific targeted chimeric antigen receptor t cells
|
|
GB201505305D0
(en)
|
2015-03-27 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel Peptides and combination of peptides for use in immunotherapy against various tumors
|
|
WO2016168766A1
(en)
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Optimized chimeric receptor t cell switches and uses thereof
|
|
EP3283113A4
(en)
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
|
AU2016265845B2
(en)
|
2015-05-15 |
2020-10-08 |
City Of Hope |
Chimeric antigen receptor compositions
|
|
AU2016264363B2
(en)
|
2015-05-19 |
2019-07-25 |
Tuhura Biosciences, Inc. |
Cancer vaccine comprising mRNA encoding a M-like-protein
|
|
IL255887B
(en)
|
2015-05-28 |
2022-09-01 |
Kite Pharma Inc |
Methods for training patients for t-cell therapy
|
|
EP3307282A4
(en)
|
2015-06-12 |
2019-05-01 |
Immunomedics, Inc. |
DISEASE THERAPY WITH CONSTRUCTS OF CHIMERIC ANTIGEN RECEPTOR (CAR) AND T-CELL (CAR-T) OR NK-CELL (CAR-NK) EXPRESSIVE CAR CONSTRUCTS
|
|
US9663756B1
(en)
|
2016-02-25 |
2017-05-30 |
Flodesign Sonics, Inc. |
Acoustic separation of cellular supporting materials from cultured cells
|
|
CN107709356A
(zh)
|
2015-06-26 |
2018-02-16 |
南加利福尼亚大学 |
用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
|
|
GB201514328D0
(en)
|
2015-08-12 |
2015-09-23 |
Sigmoid Pharma Ltd |
Compositions
|
|
GB201514874D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Cell
|
|
GB201514875D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Receptor
|
|
WO2017035362A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
|
|
US10525082B2
(en)
|
2015-09-09 |
2020-01-07 |
Seattle Children's Hospital |
Genetic engineering of macrophages for immunotherapy
|
|
US9790467B2
(en)
|
2015-09-22 |
2017-10-17 |
Qt Holdings Corp |
Methods and compositions for activation or expansion of T lymphocytes
|
|
EP4108255A1
(en)
|
2015-10-05 |
2022-12-28 |
Precision Biosciences, Inc. |
Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
|
|
US11466097B2
(en)
|
2015-10-06 |
2022-10-11 |
City Of Hope |
Chimeric antigen receptors targeted to PSCA
|
|
GB201518817D0
(en)
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Cell
|
|
GB201518816D0
(en)
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Receptor
|
|
EP3370743A4
(en)
|
2015-11-05 |
2019-04-24 |
City of Hope |
METHOD FOR PRODUCING CELLS FOR ADOPTIVE T CELL THERAPY
|
|
US20180327781A1
(en)
|
2015-11-09 |
2018-11-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Novel rna-based vector system for transient and stable gene expression
|
|
TWI724056B
(zh)
|
2015-11-19 |
2021-04-11 |
美商卡默森屈有限公司 |
Cxcr2抑制劑
|
|
TWI734715B
(zh)
|
2015-11-19 |
2021-08-01 |
美商卡默森屈有限公司 |
趨化因子受體調節劑
|
|
CA3007473A1
(en)
|
2015-12-14 |
2017-06-22 |
Bellicum Pharmaceuticals, Inc. |
Dual controls for therapeutic cell activation or elimination
|
|
US9849092B2
(en)
|
2015-12-21 |
2017-12-26 |
Gholam A. Peyman |
Early cancer detection and enhanced immunotherapy
|
|
BR112018013074A2
(en)
|
2015-12-30 |
2018-12-11 |
Novartis Ag |
immune effector cell therapies with enhanced efficacy
|
|
SG11201804038VA
(en)
|
2016-01-08 |
2018-06-28 |
Univ California |
Conditionally active heterodimeric polypeptides and methods of use thereof
|
|
IL304088A
(en)
|
2016-01-11 |
2023-08-01 |
Univ Leland Stanford Junior |
Systems containing chimeric proteins and their uses for controlling gene expression
|
|
EP3402509A4
(en)
|
2016-01-14 |
2019-07-10 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
TUMOR SPECIFIC IFNA SECRETION BY CAR T CELLS FOR RESTORING SOLID TUMOR MICRO ENVIRONMENT
|
|
BR112018015836A2
(en)
|
2016-02-05 |
2018-12-26 |
City Of Hope |
engineered t-cell administration for central nervous system cancer treatment
|
|
GB201602571D0
(en)
|
2016-02-12 |
2016-03-30 |
Autolus Ltd |
Signalling system
|
|
GB201602563D0
(en)
|
2016-02-12 |
2016-03-30 |
Autolus Ltd |
Signalling system
|
|
CA3013479A1
(en)
|
2016-02-16 |
2017-08-24 |
Carl NOVINA |
Immunotherapy compositions and methods
|
|
US11219635B2
(en)
|
2016-02-19 |
2022-01-11 |
City Of Hope |
Bi-specific aptamer
|
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
CN108884460B
(zh)
|
2016-03-19 |
2023-04-28 |
埃克苏马生物技术公司 |
淋巴细胞转导及其扩增调节的方法与组合物
|
|
RU2018136877A
(ru)
|
2016-03-22 |
2020-04-22 |
СИЭТЛ ЧИЛДРЕН'С ХОСПИТАЛ (ДиБиЭй СИЭТЛ ЧИЛДРЕН'С РИСЕРЧ ИНСТИТЬЮТ) |
Способы раннего вмешательства для профилактики или улучшения состояния токсичности
|
|
US12144850B2
(en)
|
2016-04-08 |
2024-11-19 |
Purdue Research Foundation |
Methods and compositions for car T cell therapy
|
|
EP3443001B1
(en)
|
2016-04-11 |
2025-04-30 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
|
US11136405B2
(en)
|
2016-06-06 |
2021-10-05 |
Board Of Regents, The Unviersity Of Texas System |
BAFF-R antibodies and uses thereof
|
|
CA3026640A1
(en)
|
2016-06-06 |
2017-12-14 |
City Of Hope |
Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
|
|
GB201610512D0
(en)
|
2016-06-16 |
2016-08-03 |
Autolus Ltd |
Chimeric antigen receptor
|
|
GB201610515D0
(en)
|
2016-06-16 |
2016-08-03 |
Autolus Ltd |
Cell
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
EP3484448B1
(en)
|
2016-07-13 |
2025-04-09 |
President and Fellows of Harvard College |
Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
|
|
WO2018031694A1
(en)
|
2016-08-09 |
2018-02-15 |
City Of Hope |
Chimeric poxvirus compositions and uses thereof
|
|
US9642906B2
(en)
|
2016-09-16 |
2017-05-09 |
Baylor College Of Medicine |
Generation of HPV-specific T-cells
|
|
EP3529353A4
(en)
|
2016-10-19 |
2020-05-13 |
City of Hope |
USE OF TRIPLEX-CMV VACCINE IN CAR-T-CELL THERAPY
|
|
KR102613430B1
(ko)
|
2016-10-19 |
2023-12-18 |
더 스크립스 리서치 인스티튜트 |
인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
|
|
US11116834B2
(en)
|
2016-10-19 |
2021-09-14 |
City Of Hope |
Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy
|
|
US10617720B2
(en)
|
2016-10-20 |
2020-04-14 |
Miltenyi Biotech, GmbH |
Chimeric antigen receptor specific for tumor cells
|
|
AU2016427822B2
(en)
|
2016-10-31 |
2025-01-23 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Method for treating autoimmune disease using CD4 T-cells with engineered stabilization of expression of endogennous FOXP3 gene
|
|
US20200095547A1
(en)
|
2016-12-02 |
2020-03-26 |
Darya ALIZADEH |
Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
|
|
US11408005B2
(en)
|
2016-12-12 |
2022-08-09 |
Seattle Children's Hospital |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
|
CN118546256A
(zh)
|
2016-12-13 |
2024-08-27 |
西雅图儿童医院(Dba西雅图儿童研究所) |
在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法
|
|
EP3336107A1
(en)
|
2016-12-15 |
2018-06-20 |
Miltenyi Biotec GmbH |
Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
|
|
US11590214B2
(en)
|
2016-12-21 |
2023-02-28 |
Danmarks Tekniskte Universitet |
Antigen presenting scaffolds for immune-cell manipulation
|
|
AU2018219226B2
(en)
|
2017-02-07 |
2024-12-19 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
|
CN118634339B
(zh)
|
2017-02-17 |
2025-07-01 |
珀杜研究基金会 |
用于细胞疗法的基于靶向性配体-有效负载的药物递送
|
|
ES3010559T3
(en)
*
|
2017-02-28 |
2025-04-03 |
Endocyte Inc |
Compositions and methods for car t cell therapy
|
|
WO2018165194A1
(en)
|
2017-03-06 |
2018-09-13 |
University Of Washington |
Engineered cells and agent compositions for therapeutic agent delivery and treatments using same
|
|
US20200405881A1
(en)
|
2017-03-06 |
2020-12-31 |
University Of Washington |
Cell based methods and compositions for therapeutic agent delivery and treatments using same
|
|
CA3056609A1
(en)
|
2017-03-16 |
2018-09-20 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins
|
|
MX2019011225A
(es)
|
2017-03-20 |
2020-01-21 |
|
Células t modificadas por el receptor de antígeno quimérico dirigidas a cs1 para el tratamiento de la amiloidosis al.
|
|
CN110913871B
(zh)
|
2017-05-17 |
2024-02-23 |
西雅图儿童医院(Dba西雅图儿童研究所) |
生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法
|
|
US11370842B2
(en)
|
2017-08-01 |
2022-06-28 |
City Of Hope |
Anti-IL1RAP antibodies
|
|
US20200181264A1
(en)
|
2017-08-11 |
2020-06-11 |
City Of Hope |
Bispecific antigen-binding molecule
|
|
US11311576B2
(en)
|
2018-01-22 |
2022-04-26 |
Seattle Children's Hospital |
Methods of use for CAR T cells
|
|
WO2019156795A1
(en)
|
2018-02-06 |
2019-08-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
CA3091674A1
(en)
|
2018-02-23 |
2019-08-29 |
Endocyte, Inc. |
Sequencing method for car t cell therapy
|
|
CN112262214A
(zh)
|
2018-04-12 |
2021-01-22 |
优莫佳生物制药股份有限公司 |
病毒载体及包装细胞系
|
|
CA3091490A1
(en)
|
2018-04-27 |
2019-10-31 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Rapamycin resistant cells
|
|
CA3108778A1
(en)
|
2018-08-06 |
2020-02-13 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods and compositions for stimulation of chimeric antigen receptor t cells with hapten labelled cells
|
|
SG11202100616VA
(en)
|
2018-08-07 |
2021-03-30 |
Purdue Research Foundation |
Rejuvenation of car t cell
|
|
WO2020106992A1
(en)
|
2018-11-21 |
2020-05-28 |
Umoja Biopharma, Inc. |
Multicistronic vector for surface engineering lentiviral particles
|
|
EP3993814A4
(en)
|
2019-07-05 |
2023-06-28 |
Purdue Research Foundation |
Design and efficient synthesis of lipid-fluorescein conjugates for car-t cell therapy
|
|
US20220409747A1
(en)
|
2019-09-17 |
2022-12-29 |
Purdue Research Foundation |
Fibroblast activation protein (fap)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases
|
|
CA3154281A1
(en)
|
2019-10-16 |
2021-04-22 |
Andrew Scharenberg |
Retroviral vector for universal receptor therapy
|
|
CN115697388A
(zh)
|
2020-01-30 |
2023-02-03 |
优莫佳生物制药股份有限公司 |
双特异性转导增强子
|
|
CA3169804A1
(en)
|
2020-02-04 |
2021-08-12 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods and compositions for stimulation of chimeric antigen receptor t cells with hapten labelled cells
|
|
KR20220163940A
(ko)
|
2020-02-04 |
2022-12-12 |
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 |
항-디니트로페놀 키메라 항원 수용체
|
|
CN115551555A
(zh)
|
2020-03-06 |
2022-12-30 |
普渡研究基金会 |
用于修饰car-t细胞活性的方法、化合物和组合物
|
|
CN116323656A
(zh)
|
2020-07-16 |
2023-06-23 |
优莫佳生物制药股份有限公司 |
门控衔接子靶向受体
|
|
JP2023551220A
(ja)
|
2020-11-20 |
2023-12-07 |
ウモジャ バイオファーマ インコーポレイテッド |
複数のポリヌクレオチドを送達するためのベクター系およびその使用法
|
|
MX2023008831A
(es)
|
2021-01-27 |
2023-10-19 |
Umoja Biopharma Inc |
Lentivirus para generar células que expresan receptores de antígeno quimérico anti-cd19.
|
|
AU2023285113A1
(en)
|
2022-06-09 |
2024-12-12 |
Umoja Biopharma, Inc. |
Compositions and methods for nk cell differentiation
|